Abbott will develop assay for Janssen-Pharmacyclics leukemia drug

02/22/2013 | GenomeWeb Daily News (free registration) · Yahoo

Abbott Laboratories agreed to develop a fluorescence in situ hybridization-based companion diagnostic to determine which patients will benefit from ibrutinib, an experimental chronic lymphocytic leukemia drug being developed by Pharmacyclics and Johnson & Johnson's Janssen Biotech. The test will identify high-risk CLL patients with a deletion in chromosome 17p.

View Full Article in:

GenomeWeb Daily News (free registration) · Yahoo

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
Market Access Manager Electrophysiology HEOR (AEP) - 15000003NZ
Menlo Park, CA
Sales Manager, Employer Programs
PartnerRe Health